Cargando…
Liquid biopsy genotyping in lung cancer: ready for clinical utility?
Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as e...
Autores principales: | Huang, Wei-Lun, Chen, Yi-Lin, Yang, Szu-Chun, Ho, Chung-Liang, Wei, Fang, Wong, David T., Su, Wu-Chou, Lin, Chien-Chung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392351/ https://www.ncbi.nlm.nih.gov/pubmed/28099915 http://dx.doi.org/10.18632/oncotarget.14613 |
Ejemplares similares
-
The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer
por: Huang, Wei-Lun, et al.
Publicado: (2015) -
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
por: Nigro, Maria Concetta, et al.
Publicado: (2023) -
Liquid biopsies, are we ready for prime time?
por: Normanno, Nicola, et al.
Publicado: (2023) -
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
por: Su, Po-Lan, et al.
Publicado: (2018) -
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma
por: Yang, Szu-Chun, et al.
Publicado: (2022)